Clinical trials
Transplantation Infection clinical trials
Below are recruiting transplantation infection clinical trials, each written for real people, not researchers. We’re tracking 109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04989491RecruitingPhase 4
Single-dose rituximab to prevent EBV after kidney transplant
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
StrasbourgAges 18 years+ - NCT07688759Recruiting
Immune response measurement for first CMV after transplant
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
Suzhou, JiangsuAges 18 years+ - NCT07473999Recruiting
Vaccine protection in transplant recipients
This study looks at how well vaccines work in people who have received a bone marrow or solid organ transplant. Researchers will track infections and outcomes to understand vaccine effectiveness.
Pavia, LombardyAges Any age - NCT06409819RecruitingPhase 1/Phase 2
Phage therapy for recurrent UTIs in kidney transplant patients
This trial tests a phage (virus that kills bacteria) treatment for women who have had a kidney transplant and keep getting urinary tract infections (UTIs) caused by E. coli bacteria. It aims to see if this therapy can help prevent future infections.
La Jolla, CaliforniaAges 18 years+ - NCT06311006Recruiting
Safety registry for fecal transplant for C. diff
This registry tracks people who receive a fecal microbiota transplant (FMT) for a serious or repeat C. diff infection. It helps doctors better understand how safe and effective FMT is in real-world use.
ParisAges 18 years+ - NCT05711667RecruitingPhase 3
Letermovir to prevent CMV after stem cell transplant in kids
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Birmingham, AlabamaAges 2–18 - NCT05664126RecruitingPhase 2
Donor immune-cell treatment for stubborn CMV or adenovirus after transplant
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
Memphis, TennesseeAges Up to 18 years - NCT05653232Recruiting
Preventing hepatitis C in kidney transplant recipients using antiviral pills
This study tests antiviral medicine given around the time of a kidney transplant to prevent hepatitis C infection when the donor has hepatitis C. It may help uninfected recipients stay hepatitis C–free after receiving the kidney.
La Jolla, CaliforniaAges 18 years+ - NCT04691622RecruitingPhase 1
Treat chronic norovirus using donor immune cells
This Phase 1 study tests whether giving immune cells made from a donor can help children and adults with long-lasting (chronic) norovirus infection. It’s aimed at people whose immune system is weakened after a stem cell transplant, solid organ transplant, or due to primary immune problems.
Washington D.C., District of ColumbiaAges 3 months–80 years - NCT03378102RecruitingEarly Phase 1
AdV-targeted T cells for adenovirus after bone marrow transplant
This trial tests a custom immune cell treatment (T cells made to recognize adenovirus) for people whose adenovirus infection is not improving or who cannot tolerate standard antiviral medicines after a bone marrow transplant. It aims to help your body control the virus and prevent organ complications.
Cleveland, OhioAges 3 months+ - NCT05588492RecruitingPhase 4
Rifamycin treatment to prevent TB after kidney transplant
This study looks at whether a rifamycin-containing medicine plan is safe and effective at preventing latent (hidden) TB after a kidney transplant. If your TB test shows you likely have hidden TB, you would be offered treatment to reduce the chance it becomes active TB.
TaipeiAges 20 years+ - NCT07374094Recruiting
Understanding C. difficile infection and treatment effects
This study is tracking patients with a confirmed C. difficile infection to understand how the body responds and how treatments work. You may be asked to do follow-up visits for up to 5 years.
UmeåAges 18 years+ - NCT06659952Recruiting
HIV+ donor hearts for HIV+ recipients
This trial tests whether hearts from donors who had HIV can be safely transplanted into people with HIV who need a heart transplant. It may offer a new option for those on the waiting list.
Dallas, TexasAges 18 years+ - NCT03818334RecruitingPhase 2/Phase 3
Cyclophosphamide after transplant for blood cancer without sibling donor
This trial studies giving cyclophosphamide after a stem cell transplant when there is no matched sibling donor, but a well-matched unrelated donor is available. It aims to improve outcomes for people with blood cancers undergoing this transplant.
São Paulo, São PauloAges 1–75 - NCT04942886Enrolling by invitation
Preventing hepatitis B reactivation after stem cell transplant
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
SeoulAges 19–70 - NCT07266467RecruitingPhase 4
Preventing CMV After First Kidney Transplant
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
Xi'an, ShaanxiAges 18 years+ - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07524062Recruiting
Thermal Imaging to Predict Surgical Wound Healing
This study uses thermal imaging (a camera that detects heat patterns on skin) to predict how well skin wounds will heal after surgery to remove suspicious or cancerous skin lesions. The goal is to identify which patients might have healing problems early so doctors can provide extra care.
Leuven, Vlaams BrabantAges 18 years+ - NCT04293042RecruitingEarly Phase 1
BK virus treatment using donor immune cells after transplant
This early-phase study tests whether immune cells made from a donor (T cells) can treat BK virus infection in people whose immune system is weak after a stem cell transplant or chemotherapy. It may help control the virus causing bladder/urinary symptoms.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT07381738RecruitingPhase 2
Cord blood transplant for Epstein-Barr virus diseases
This trial uses donated umbilical cord blood (a type of stem cell transplant) to treat people with serious illnesses caused by the Epstein-Barr virus. It's an option for those whose disease has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 14–80 - NCT07875595Recruiting
Immune markers for predicting problems after liver transplant
This study looks at blood markers of the immune system to see if they can predict complications after a liver transplant. It aims to help doctors personalize care and catch problems early.
Pilar, Buenos AiresAges 18 years+ - NCT05284877Recruiting
Study of HPV and skin cancer after organ transplant
This study looks at how human papillomavirus (HPV) and skin cancer behave in people who have had a solid organ transplant. It also includes healthy people for comparison, to understand what might be different after transplant and immune medicines.
Copenhagen NV, Capital RegionAges 18 years+ - NCT06059391RecruitingPhase 2
Vaccine for stem cell donors to prevent CMV
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
Duarte, CaliforniaAges 18–75 - NCT07665372Recruiting
Liver transplant from donors with HIV for people with HIV
This study tests whether giving people with HIV a liver from an HIV-positive donor is safe and works well. It looks at infections, cancer risks, and long-term health after transplant.
Phoenix, ArizonaAges 18 years+
Hear when a new Transplantation Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for transplantation infection?
- Yes. Clin2 currently lists 109 recruiting transplantation infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a transplantation infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a transplantation infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.